Latest News
ROCK inhibition promising drug to preserve the blood-brain barrier
Nov. 6, 2024: Bioaxone BioSciences is pleased to announce the publication of article “The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury” The preclinical data shows that NRL-1049 is a promising drug candidate to preserve the blood brain barrier after brain injury. Click here for a link to the publication.
Dr McKerracher advisor to International Space Station
July 2024 Lisa McKerracher accepted an invitation to serve on the National Lab User Advisory Committee for the International Space Station (ISS). The ISS is a unique environment to study cell behavior, and regenerative medicine because in microgravity cell growth, differentiation, morphology, and adhesion are different and may more faithfully mimic in vivo development processes. The User Advisory committees recommends research priorities and provides assistance for ISS user community issues.
Patent issued to protect BA-210, a Rho inhibitor for treatment of SCI
May 18 2022: Bioaxone announced issuance of patent US 11,324,802 to protect the composition and methods of making their Rho inhibitor, a C3 fusion protein called BA-210. BA-210 has been tested in Phase 1b and Phase 2/3 clinical trials for the treatment of acute spinal cord injury.
Novel self-delivering RNAi targeting PTEN for SCI
August 24, 2021: BioAxone announced issuance of patent US11,098,308 covering a method of treatment of spinal cord injury with BA-434, a novel self-delivering-rxRNA compound that targets transient, non-permanent PTEN suppression to promote axon regeneration and reduce paralysis. RNA silencing is a method to block expression and silencing PTEN in neurons promotes long-distance regrowth of injured axons. It is being developed for treatment of spinal cord injury.
IND filed to advance NRL-1049 for treatment of CCM
Boston, Jan 9, 2023. Licensee Neurelis announced the successful filing of an IND for NRL-1049, a ROCK inhibitor developed by BioAxone with potential to treat cerebral cavernous malformation (CCM) an . For the full press release click here.
BioAxone partners with Neurelis for ROCK2-selective inhibitor
June 21, 2021: BioAxone signed a license with Neurelis, a San diego-based company for clinical development of BA-10499 to treat cerebral cavernous malformation. Dr. McKerracher noted: “Neurelis is an ideal partner to develop BA-1049 because they are a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for treatment of epilepsy and orphan diseases of high unmet medical need.
For the full release please click here